Article

Breast Cancer May Change a Patient's Microbiome

Bacterial differences were seen between tissue from patients with and without breast cancer.

Researchers in a recent study discovered breast microbiome differences among healthy and cancerous tissue.

“Our research found that breast tissue samples obtained in the operating room under sterile conditions contain bacterial DNA, even when there is no sign of infection. Furthermore, we identified significant differences in the breast tissue microbiome of women with cancer versus women without cancer,” said researcher Tina Hieken, MD. “Our work confirmed the presence of a distinct breast tissue microbiome and that it is different than the microbiome of the overlying breast skin.”

While risk factors are established, current prediction models are not effective at identifying risks for specific women, according to a study published by Scientific Reports. Previous research has found that microbiome changes have been seen in various cancers, such as stomach, colon, liver, lung, and skin.

The current study stated that it is still unclear whether a new virulent pathogenic strain or the absence of a beneficial strain could increase cancer risk, according to the study. Researchers believe their findings could lead to further research to identify causes of breast cancer, and create new microbial-based prevention treatments.

“There is mounting evidence that changes in the breast microbiome may be implicated in cancer development and the aggressiveness of cancer and that eliminating dangerous microorganisms or restoring normal microbiota may reverse this process,” said researcher Nick Chia, PhD.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com